title: The venous antithrombotic profile of naroparcil in the rabbit.
abstract: The venous antithrombotic profile of naroparcil or (4-[4-cyanobenzoyl]-phenyl)-1.5-dithio-beta-D-xylopyranoside was investigated in the rabbit following single i.v. and oral administration. Naroparcil attenuated thrombus development in a Wessler stasis model of venous thrombosis (jugular vein) employing bovine factor Xa as a thrombogenic stimulus giving ED50 values of 21.9 mg/kg and 36.0 mg/kg after respectively i.v. and oral administration. Venous antithrombotic activity was maximal 2-3 h after i.v. administration and 4-8 h after oral administration. Four hours after the oral administration of maximal antithrombotic (Wessler model, factor Xa) doses (100 and 400 mg/kg), naroparcil had no significant effect on bleeding time. In platelet poor plasma obtained from animals treated 4 h previously with various doses (25 to 400 mg/kg) of naroparcil, there was no detectable anti-factor Xa nor antithrombin activity. Similarly, naroparcil had no effect on APTT nor on thrombin time. A sensitized thrombin time (to about 35 s) was modestly but significantly increased following oral administration of the compound at 400 mg/kg. However, thrombin generation by the intrinsic pathway was reduced in a dose-related manner, maximal reduction being 65% at 400 mg/kg. The same dose of naroparcil enhanced the formation of thrombin/heparin cofactor II complexes at the expense of thrombin/antithrombin III complexes in plasma incubated with (125I)-human alpha-thrombin and induced the appearance of dermatan sulfate-like material in the plasma of treated rabbits, as measured by a heparin cofactor II-mediated thrombin inhibition assay.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Fournier S.C.A. Laboratories, Daix, France.
authors.forename: J
authors.initials: J
authors.lastname: Millet
authors.forename: J
authors.initials: J
authors.lastname: Theveniaux
authors.forename: N L
authors.initials: NL
authors.lastname: Brown
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000991:Antithrombins / Q000494:pharmacology*; D001777:Blood Coagulation / Q000187:drug effects; D006470:Hemorrhage / Q000139:chemically induced; D007601:Jugular Veins; D008297:Male; D010314:Partial Thromboplastin Time; D011817:Rabbits; D013865:Thioglycosides / Q000494:pharmacology*; D013918:Thrombin Time; D013927:Thrombosis / Q000517:prevention & control*
chemical_list: D000991:Antithrombins; D013865:Thioglycosides; C092014:naroparcil